Company Overview and News

0
Glenmark shares jump over 2%

2018-07-17 thehindubusinessline
Shares of Glenmark Pharmaceuticals climbed as much as 2.1 per cent to Rs 563 as the company has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood.
GLENMARK 532296 GLKQY

0
Glenmark Pharmaceuticals gets USFDA nod for cholesterol lowering drug

2018-07-17 moneycontrol
Glenmark Pharmaceuticals has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood. The approval has been granted by the United States Food and Drug Administration (USFDA) in the strengths of 1.875 grams/packet and 3.75 grams/packet, the company said in a BSE filing today.
GLENMARK 532296 GLKQY

0
Glenmark Pharmaceuticals Limited - News Clarification

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

0
Glenmark Pharma gains 1% on USFDA nod; acquires 100% in Zorg

2018-07-17 moneycontrol
Shares of Glenmark Pharma added 1.5 percent in the opening trade on Tuesday as company received final approval from USFDA for Colesevelam Hydrochloride.
GLENMARK 532296 GLKQY

0
Glenmark Pharmaceuticals Limited - Press Release

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

0
Glenmark Pharmaceuticals Limited - Acquisition

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

0
Glenmark Pharmaceuticals Limited - News Clarification

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

0
Glenmark falls 2.4% as CCI slaps Rs 47 cr penalty

2018-07-16 thehindubusinessline
Shares of Glenmark Pharmaceuticals fell as much as 2.4 per cent to Rs 551.50, their lowest since June 8, on CCI penalty.
GLENMARK 532296 AUROPHARMA 524804 ARBQY GLKQY

0
Glenmark Pharmaceuticals Limited - Credit Rating

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

0
Glenmark launches Akynzeo in India under licensing pact with Helsinn

2018-07-12 moneycontrol
Glenmark Pharmaceuticals today launched Akynzeo, a drug used for prevention chemotherapy-induced nausea and vomiting, in India and Nepal under an exclusive licensing pact with Swiss pharma group, Helsinn. Akynzeo is an oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg. It is administered in a single capsule and offers 5-day prophylaxis from of both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).
GLENMARK 532296 GLKQY

30
Your Daily Pharma Scoop: IPO Review - Aptinyx Surges, Kezar Progresses, Neon Slumps

2018-07-11 seekingalpha
Aptinyx (APTX) priced its IPO at $16.00. 6.4M common stock shares were offered. Additional 959,999 shares were on underwriters over-allotment. Gross proceeds initially expected was ~102.4M, but reached $117.8M by the time of closing. The shares opened at $17.40 on June 21. The IPO closed on June 25.
GLENMARK APTX ALPMF AUPH DEPO LLY GSK GLKQY CADILAHC CDLYY 4503 MYL 532321 ALPMY AUP NTGN IMMU BMS 532296 JNJ NVS KZR PFE

1
3 PE firms in talks to buy stake in Glenmark API business

2018-07-09 livemint
Mumbai: Three private equity (PE) funds are in early talks to acquire a significant stake in Glenmark Pharmaceuticals Ltd’s active pharmaceutical ingredient (API) business, said two people directly aware of the development. Private equity funds Carlyle Group, Advent International and China’s Fosun International are holding separate talks with Glenmark to pick up the API business, which will be demerged into a separate entity, the people cited above said, requesting anonymity.
GLENMARK FOSUF 532296 0656 CG FOSUY GLKQY

0
Glenmark Pharmaceuticals Limited - Press Release

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

0
Pharma industry recovers from GST pangs, poised for double digit growth

2018-06-29 moneycontrol
The Indian pharmaceutical market returned to double digit growth of 10.8 percent in May for the first time in over a year indicating the pangs of transitioning to the Goods and Service Tax (GST) regime have been left behind.
GLENMARK 532296 GLKQY

0
USFDA approves first product from Glenmark#39;s US plant

2018-06-19 moneycontrol
Glenmark Pharmaceuticals today said the US health regulator has approved the first product from its Monroe, North Carolina based manufacturing facility.
GLENMARK 532296 GLKQY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 006698755